Pasithea Therapeutics Corp. (KTTA) has a consensus analyst rating of Buy, based on 1 analyst covering the stock. Of those, 1 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for KTTA is $3.00, representing a +315.5% upside from the current price of $0.722. Price targets range from a low of $3.00 to a high of $3.00.
